Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.
You may also be interested in...
Digital Revolution Will Not Be Free: Facilitating OTC Switches, Engaging Consumers
Digital technologies could transform how consumers shop for OTC drugs in stores, but costs could be significant, say industry consultants. Marketers are looking to create digital “touch points” such as interactive kiosks to create two-way communication between brands and customers.
Digital Revolution Will Not Be Free: Facilitating OTC Switches, Engaging Consumers
Digital technologies could transform how consumers shop for OTC drugs in stores, but costs could be significant, say industry consultants. Marketers are looking to create digital “touch points” such as interactive kiosks to create two-way communication between brands and customers.
Allegra-D Joins ‘Common Cold’ Club In OTC Antihistamine Market
Allegra-D has competed in the OTC antihistamine space without including “relief of nasal congestion due to the common cold” in its indications since its 2011 launch through Sanofi’s Chattem business.